RTW INVESTMENTS, LP - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 50 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2017. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.

Quarter-by-quarter ownership
RTW INVESTMENTS, LP ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q4 2021$9,742,000
-52.0%
2,504,493
-47.1%
0.14%
-53.6%
Q3 2021$20,306,000
+12.1%
4,733,323
-20.8%
0.31%
+12.1%
Q2 2021$18,114,000
-9.0%
5,978,3550.0%0.27%
-12.2%
Q1 2021$19,908,000
-6.2%
5,978,3550.0%0.31%
-12.6%
Q4 2020$21,223,000
+13.4%
5,978,3550.0%0.36%
-21.1%
Q3 2020$18,712,000
+49.7%
5,978,355
-13.0%
0.45%
+28.1%
Q2 2020$12,502,000
+80.2%
6,869,2810.0%0.35%
+17.7%
Q1 2020$6,938,000
-56.0%
6,869,281
+21.2%
0.30%
-49.7%
Q4 2019$15,754,000
+85.7%
5,666,754
+1.9%
0.59%
+17.6%
Q3 2019$8,484,000
-26.3%
5,562,967
+0.5%
0.50%
-17.9%
Q2 2019$11,509,000
-41.7%
5,533,093
+0.4%
0.62%
-54.3%
Q1 2019$19,727,000
+18.8%
5,510,223
+27.1%
1.35%
-12.9%
Q4 2018$16,606,000
-57.0%
4,335,746
+6.1%
1.55%
-33.1%
Q3 2018$38,602,000
+2.4%
4,084,904
-20.9%
2.31%
-15.0%
Q2 2018$37,708,000
+46.4%
5,165,499
+0.3%
2.72%
+11.0%
Q1 2018$25,758,000
-1.0%
5,151,6150.0%2.45%
-43.6%
Q4 2017$26,016,000
-20.3%
5,151,615
-2.2%
4.34%
-23.6%
Q3 2017$32,651,000
+74.1%
5,266,280
+1.1%
5.69%
+43.8%
Q2 2017$18,755,000
+299.0%
5,209,823
+260.1%
3.95%
+219.6%
Q1 2017$4,701,0001,446,5871.24%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q4 2017
NameSharesValueWeighting ↓
Two Seas Capital LP 825,569$3,211,0002.46%
GREAT POINT PARTNERS LLC 668,907$2,602,0000.58%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 270,000$1,050,0000.47%
QCM Cayman, Ltd. 10,205$40,0000.24%
Pitti Group Wealth Management, LLC 50,000$195,0000.22%
RTW INVESTMENTS, LP 2,504,493$9,742,0000.14%
Hudson Bay Capital Management LP 1,805,700$7,024,0000.07%
Quinn Opportunity Partners LLC 276,485$1,076,0000.07%
Kepos Capital LP 200,000$778,0000.06%
XTX Topco Ltd 29,026$113,0000.06%
View complete list of ARBUTUS BIOPHARMA CORP shareholders